Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
49 results about "Wet age-related macular degeneration" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Wet Macular Degeneration. The wet/neovascular type affects approximately 10-15% of individuals with age-related macular degeneration, but accounts for approximately 90% of all cases of severe vision loss from the disease. In wet age-related macular degeneration, abnormal blood vessels under the retina begin to grow toward the macula.
Non-Linear Multiblock Copolymer-Drug Conjugates for the Delivery of Active Agents
ActiveUS20130272994A1Improve propertiesControlled drug and drug release profilePowder deliverySenses disorderUveitisDisease
Non-linear multiblock copolymer-drug conjugates for the treatment and prevention of diseases and disorders of the eye are provided. The polymer-drug conjugates can form nanoparticles, microparticles, and implants that are capable of effectively delivering therapeutic levels of one or more active agents for an extended period of time. Administration to the eye of an active agent in the form of a non-linear multiblock copolymer-drug conjugate produces decreased side effects when compared to administration of the active agent alone. Also provided are methods of treating intraocular neovascular diseases, such as wet age-related macular degeneration as well as diseases and disorders of the eye associated with inflammation, such as uveitis.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Use of compounds that interfere with the Hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
InactiveUS20060276391A1High unmet needControl rateBiocideOrganic active ingredientsDiabetic retinopathyHedgehog signaling pathway
The present invention concerns the use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and / or reversing ocular diseases related with ocular neovascularization. Partcularly, the above-mentioned diseases are (wet) age-related macular degeneration, (proliferative) diabetic retinopathy, neovascular glaucoma, retinal vein occlusion, or retinopathy of prematurity (ROP).
Owner:FOND AZIONE TELETHON
Methods and compositions for treating macular degeneration
InactiveUS20050043220A1Reduce absorptionSenses disorderPeptide/protein ingredientsVascular endothelial growth factorAnti vegf
This invention relates to methods of treating age-related macular degeneration (AMD). In particular, this invention provides methods of treating all forms of wet, age-related macular degeneration. The method of the invention is directed to the administration of an anti-vascular endothelial growth factor (anti-VEGF) compound to treat wet AMD.
Owner:(OSI) EYETECH INC
Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
ActiveUS20140039048A1Reduce rod energy demandImprove retinal functionBiocideSenses disorderDiseaseDiabetic retinopathy
Methods are provided herein for the treatment of ophthalmic diseases or conditions such as an ophthalmic disease or disorder associated with diabetes in a patient. Also provided herein are methods of treating retinopathy of prematurity in a patient. Further, provided herein are methods for treating wet age-related macular degeneration in a patient. The methods comprise administration of compounds disclosed herein to a patient in need thereof that inhibit or slow one or more signs or symptoms of such conditions.
Owner:ACUACELA INC
Devices and methods for treating occlusion of the ophthalmic artery
There is provided herein a disclosure and specification of invention(s) relating to devices and methods for percutaneous access and treatment of vascular structures in the rear of the eye, including treatment for the symptoms related to Wet Age Related Macular Degeneration by removal of stenosis of the OA, thereby restoring normal, or near normal, blood flow to the rear of the eye, including the retina and associated structures. Also provided herein is a disclosure and specification of invention(s) relating to methods and devices for selective manipulation of Intraocular Pressure (IOP) be means of mechanical force for the purpose of inducing retrograde flow in the ophthalmic vasculature.
Owner:OCUDYNE INC
STABLE LIQUID FORMULATION OF FUSION PROTEIN WITH IgG Fc DOMAIN
ActiveUS20160376342A1Long-term stabilityReduce storage conditionsSenses disorderPeptide/protein ingredientsDiseaseVEGF receptors
A stable liquid formulation includes a fusion protein having an Fc domain of a human immunoglobulin G (IgG), in particular, a protein in which an Fc domain of a human immunoglobulin G (IgG) and a soluble extracellular domain of a vascular endothelial growth factor (VEGF) receptor are fused (e.g., aflibercept)). A composition for stabilizing a protein and a method for stabilizing a protein in which an Fc domain of an IgG and a soluble extracellular domain of a VEGF receptor are fused are disclosed. The present invention improves therapeutic effects on various ophthalmic diseases (e.g., retinal vein occlusion, diabetic macular edema, choroidal neovascularization and wet age-related macular degeneration, etc.) caused by abnormal angiogenesis, while pursuing stabilization of bioactivity through a stable liquid formulation suitable for intravitreal injection of an anti-VEGF-Fc fusion protein including aflibercept.
Owner:ALTEOGEN
Formulations for treatment of ocular diseases or conditions
Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium; nondispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including via intraocular or periocular administration, or placement proximate to a site of a disease or condition to be treated in a subject. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration, or wet age- related macular degeneration.
Owner:SANTEN PHARMA CO LTD
Compositions and Methods for the Treatment of Intraocular Neovascularization and/or Leakage
The invention provides compositions and methods for the treatment of intraocular neovascularization and / or leakage including wet age-related macular degeneration. The compositions preferably use tyrosine kinase inhibitors with an IC50 for VEGFR2 of 20 nanomolars or less and an IC50 for c-MET of 20 nanomolars or less.
Owner:HORN GERALD
Methods and compositions for treating macular degeneration
InactiveUS20070027102A1Peptide/protein ingredientsGenetic material ingredientsVascular endothelial growth factorAnti vegf
This invention relates to methods of treating age-related macular degeneration (AMD). In particular, this invention provides methods of treating all forms of wet, age-related macular degeneration. The method of the invention is directed to the administration of an anti-vascular endothelial growth factor (anti-VEGF) compound to treat wet AMD.
Owner:(OSI) EYETECH INC
Stable liquid formulation of fusion protein with IgG Fc domain
A stable liquid formulation includes a fusion protein having an Fc domain of a human immunoglobulin G (IgG), in particular, a protein in which an Fc domain of a human immunoglobulin G (IgG) and a soluble extracellular domain of a vascular endothelial growth factor (VEGF) receptor are fused (e.g., aflibercept)). A composition for stabilizing a protein and a method for stabilizing a protein in which an Fc domain of an IgG and a soluble extracellular domain of a VEGF receptor are fused are disclosed. The present invention improves therapeutic effects on various ophthalmic diseases (e.g., retinal vein occlusion, diabetic macular edema, choroidal neovascularization and wet age-related macular degeneration, etc.) caused by abnormal angiogenesis, while pursuing stabilization of bioactivity through a stable liquid formulation suitable for intravitreal injection of an anti-VEGF-Fc fusion protein including aflibercept.
Owner:ALTEOGEN
Treatment of age-related macular degeneration
InactiveUS20100316731A1Inhibit progressSlowing or preventing the onset of wet AMDBiocideSenses disorderDry age-related macular degenerationWet age-related macular degeneration
Methods and compounds are disclosed for treating dry age-related macular degeneration, and preventing or delaying the onset of wet age-related macular degeneration.
Owner:WEINSTOCK JOSEPH +1
Diagnostic method and system for detecting early age macular degeneration, maculopathies and cystoid macular edema post cataract surgery
InactiveUS9144379B1Easy to detectOthalmoscopesCystoid macular oedemaWet age-related macular degeneration
A retinoscopic device, technique and scale for estimating the reflectance of the macula pigment optical density (MPOD) in normal and abnormal eyes in order to detect early pathology of the retinal pigment epithelium and photoreceptors thus screening for macular pathology the most prevalent of which is Age-related Macular Degeneration (AMD) and retinal edema and cystoid macular edema post cataract surgery.
Owner:SIMS CLINTON NORTON
Treatment of Ocular Diseases with Fully-Human Post-Translationally Modified Anti-VEGF Fab
Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina / vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.
Owner:REGENXBIO
Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
ActiveUS9957224B2Reduce rod energy demandImprove retinal functionSenses disorderOrganic chemistryDiseaseDiabetic retinopathy
Owner:ACUACELA INC
Ophthalmic Formulations of Squalamine
The invention relates to ophthalmic formulations of squalamine or its pharmaceutically acceptable salts for the treatment of conditions of the eye such as, for example, wet age-related macular degeneration (wet AMD), choroidal neovascularization, retinopathy, dry age-related macular degeneration (dry AMD), polypoidal choroidal vasculopathy, neovascularization following ocular surgery, macular edema, retinal venous occlusion, subchoroidal neovascularization, retinal epithelial detachment, pterygum or foveal geographic atrophy of the retinal pigment epithelium.
Owner:OXEA GMBH +1
Compositions and methods for inhibiting factor d
ActiveUS20180051287A1Inhibit functioningOrganic active ingredientsDrug compositionsGeographic atrophyDry age-related macular degeneration
The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease.
Owner:396419 B C LTD
Photodynamic therapy for conditions of the eye
ActiveUS9226917B2Acceptable visual acuity outcomesAcceptable safety profileOrganic active ingredientsSenses disorderDiseasePorphyrin
Owner:BAUSCH LOMB IRELAND LTD
Devices and Methods for Treating Occlusion of the Ophthalmic Artery
There is provided herein a disclosure and specification of invention(s) relating to devices and methods for percutaneous access and treatment of vascular structures in the rear of the eye, including treatment for the symptoms related to Wet Age Related Macular Degeneration by removal of stenosis of the OA, thereby restoring normal, or near normal, blood flow to the rear of the eye, including the retina and associated structures. Also provided herein is a disclosure and specification of invention(s) relating to methods and devices for selective manipulation of Intraocular Pressure (IOP) be means of mechanical force for the purpose of inducing retrograde flow in the ophthalmic vasculature.
Owner:OCUDYNE INC
Dual-target fusion protein and preparation method and use thereof
The invention provides a dual-target fusion protein, which contains VEGF receptors and cell membrane fragments of PDGF beta receptors. Through the optimized combination of functional fragments, the present invention improves the binding ability of the fusion protein and the dual-target VEGF and PDGF β, can effectively inhibit the proliferation of new blood vessels, and achieve the treatment of neovascular proliferation diseases related to VEGF and PDGF β, such as tumor and wet age-related macular degeneration (AMD).
Owner:殷跃云
Compositions and methods for inhibiting Factor D
ActiveUS10174325B2Organic active ingredientsDrug compositionsGeographic atrophyDry age-related macular degeneration
Owner:396419 B C LTD
Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase
InactiveUS20150328337A1Increase volumeIncrease the amount addedPeptide/protein ingredientsLigasesDiabetic retinopathyDry age-related macular degeneration
An isolated polynucleotide encoding human glutamate cysteine ligase and human glutathione synthase, as well as expression constructs, vectors and pharmaceutical compositions comprising the same, are provided herein. Methods for use of these compositions in the treatment oxidative stress related diseases, including, for example, atherosclerosis, Parkinson's disease, heart failure, myocardial infarction, Alzheimer's disease, diabetes, chronic lung disease, diseases associated with mitochondrial dysfunction, diseases associated with chronic inflammation, retinitis pigmentosa, wet age related macular degeneration, dry age related macular degeneration, diabetic retinopathy, Lebers optic neuropathy, and optic neuritis are also provided.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Compositions and methods for the treatment of intraocular neovascularization and/or leakage
Owner:HORN GERALD
TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF Fab
PendingUS20200277364A1Improve the level ofLess riskSenses disorderGenetic material ingredientsDiabetic retinopathyAntigen
Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina / vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Optical Imaging
InactiveUS20090232741A1High affinityUltrasonic/sonic/infrasonic diagnosticsIn-vivo radioactive preparationsAngiogenesis growth factorRadiology
This invention relates to a method for imaging of wet age-related macular degeneration (AMD) using a contrast agent comprising a vector attached to an optical imaging reporter, wherein the vector has affinity for receptors associated with angiogenesis. The invention further provides such methods for monitoring the effect of treatment of AMD.
Owner:GE HEALTHCARE AS
Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
ActiveUS10159743B2Improve propertiesControlled drug and drug release profilePowder deliverySenses disorderUveitisDisease
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Anti-s1p antibody treatment of patients with ocular disease
ActiveUS20130058951A1Small sizeDecreasing and resolving retinal pigment epithelial detachmentSenses disorderImmunoglobulins against growth factorsDiseasePigment epithelial detachment
The present invention relates to methods that involve administration of an anti-S1 P antibody or antibody fragment or derivative to a subject having or suspected of having an ocular disease or condition, including one involving choroidal neovascularization, in order to achieve a desired effect. Such effects include reducing the size of a choroidal neovascularization lesion in the eye, decreasing or resolving retinal pigment epithelial detachment, decreasing central retinal lesion thickness, and preserving or improving visual acuity. Pharmaceutical compositions comprising an anti-S1 P antibody for ocular administration are also provided. The compositions and methods are particularly useful for treating subjects having age-related macular degeneration, particularly exudative or wet age-related macular degeneration.
Owner:APOLLO ENDOSURGERY INC
Application of bortezomib and preparation of bortezomib to preparation of medicine for treating choroidal neovascularization related diseases and preparation method of eye drops
PendingCN112263670ALittle side effectsGood curative effectSenses disorderDipeptide ingredientsChoroid membranePharmaceutical drug
The invention discloses application of bortezomib and preparation of bortezomib to preparation of a medicine for treating choroidal neovascularization related diseases and a preparation method of eyedrops. A protease complex inhibitor bortezomib is injected into a vitreous cavity or bortezomib eye drops are used on the ocular surface, the bortezomib and the preparation of bortezomib can be used for treating choroidal neovascularization related fundus diseases such as treatment of wet age-related macular degeneration, the side effect is small, and the curative effect is good.
Owner:WENZHOU MEDICAL UNIV
Predictive Markers Useful in the Treatment of Wet Age-Related Macular Degeneration
The invention is directed to the use of biomarkers to determine responsiveness of an individual with wet AMD to treatment with a VEGF antagonist, to diagnose and distinguish dry and wet AMD and to determine the risk of conversion of a dry AMD disease to a wet AMD disease.
Owner:MAINTECT GMBH
Protein Hydrogels For Treatment Of Neovascular Disease
InactiveUS20190380957A1Improve responseReduce vascular leakageAerosol deliveryTetrapeptide ingredientsDiabetic retinopathyDisease
A mimic of an anti-angiogenic peptide is combined with a self-assembling peptide hydrogel to provide improved treatment for pathological neovascularization management. Pathological neovascularization may cause or worsen intraocular posterior segment diseases, such as diabetic retinopathy (DR) and wet age-related macular degeneration (wet AMD). The attachment of a therapeutic anti-angiogenic motif to a fibrillizing peptide backbone that undergoes nanofibrous self-assembly into an injectable hydrogel was found beneficial for the treatment of aberrant neovascularization. The peptide persists for extended periods in a target site for prolonging the therapeutic timeframe. This injectable hydrogel therapy may unlock potential clinical routes for treating many neovascular diseases.
Owner:NEW JERSEY INSTITUTE OF TECHNOLOGY
Buffered formulations of bevacizumab for use of treating diseases
The invention provides buffered aqueous formulations of bevacizumab. The invention further provides methods of making buffered formulations of bevacizumab. The invention provides methods of treating eye disorders, particularly wet age-related macular degeneration and macular edema by administering the buffered antibody compositions of the disclosure.
Owner:前瞻疗法公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com